ONO-4578 + ONO-4538 + Docetaxel + Ramucirumab
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Jun 1, 2021 → Dec 31, 2026
NCT ID
NCT06542731About ONO-4578 + ONO-4538 + Docetaxel + Ramucirumab
ONO-4578 + ONO-4538 + Docetaxel + Ramucirumab is a phase 1 stage product being developed by Ono Pharmaceutical for Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06542731. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06542731 | Phase 1 | Active |
Competing Products
20 competing products in Non-small Cell Lung Cancer